Table 3.
Proportion of participants with relevant prescriptions (main medication) and extreme phenotypes of the evaluated cytochromes, catalytic subunit, and transporters in the cardiovascular drug collectives.
| Collective | Prescription | Extreme phenotype (predicted) | Gene | Participants affected | Percentage (within collective) |
|---|---|---|---|---|---|
| A/T | Apixaban | PF | ABCB1 | 229 | 2.8 |
| Apixaban | PF | VKORC1 | 143 | 1.7 | |
| Apixaban | PM | CYP2C9 | 38 | 0.5 | |
| Apixaban | PM | CYP2C19 | 23 | 0.3 | |
| Apixaban | UM | CYP2C19 | 59 | 0.7 | |
| Clopidogrel | PF | ABCB1 | 523 | 6.3 | |
| Clopidogrel | PF | VKORC1 | 333 | 4.0 | |
| Clopidogrel | PM | CYP2C9 | 96 | 1.2 | |
| Clopidogrel | PM | CYP2C19 | 56 | 0.7 | |
| Clopidogrel | UM | CYP2C19 | 113 | 1.4 | |
| Clopidogrel+ASS | PF | ABCB1 | 10 | 0.1 | |
| Clopidogrel+ASS | PF | VKORC1 | 10 | 0.1 | |
| Clopidogrel+ASS | PM | CYP2C9 | 2 | 0.0 | |
| Clopidogrel+ASS | PM | CYP2C19 | 1 | 0.0 | |
| Clopidogrel+ASS | UM | CYP2C19 | 5 | 0.1 | |
| Dabigatranetexilat | PF | ABCB1 | 63 | 0.8 | |
| Dabigatranetexilat | PF | VKORC1 | 37 | 0.4 | |
| Dabigatranetexilat | PM | CYP2C19 | 7 | 0.1 | |
| Dabigatranetexilat | PM | CYP2C9 | 7 | 0.1 | |
| Dabigatranetexilat | UM | CYP2C19 | 15 | 0.2 | |
| Edoxaban | PF | ABCB1 | 40 | 0.5 | |
| Edoxaban | PF | VKORC1 | 29 | 0.3 | |
| Edoxaban | PM | CYP2C9 | 7 | 0.1 | |
| Edoxaban | PM | CYP2C19 | 3 | 0.0 | |
| Edoxaban | UM | CYP2C19 | 12 | 0.1 | |
| Phenprocoumon | PF | ABCB1 | 315 | 3.8 | |
| Phenprocoumon | PF | VKORC1 | 215 | 2.6 | |
| Phenprocoumon | PM | CYP2C9 | 47 | 0.6 | |
| Phenprocoumon | PM | CYP2C19 | 30 | 0.4 | |
| Phenprocoumon | UM | CYP2C19 | 63 | 0.8 | |
| Prasugrel | PF | ABCB1 | 103 | 1.2 | |
| Prasugrel | PF | VKORC1 | 89 | 11 | |
| Prasugrel | PM | CYP2C9 | 17 | 0.2 | |
| Prasugrel | PM | CYP2C19 | 8 | 0.1 | |
| Prasugrel | UM | CYP2C19 | 29 | 0.3 | |
| Rivaroxaban | PF | ABCB1 | 523 | 6.3 | |
| Rivaroxaban | PF | VKORC1 | 369 | 4.4 | |
| Rivaroxaban | PM | CYP2C9 | 97 | 1.2 | |
| Rivaroxaban | PM | CYP2C19 | 70 | 0.8 | |
| Rivaroxaban | UM | CYP2C19 | 109 | 1.3 | |
| Ticagrelor | PF | ABCB1 | 148 | 1.8 | |
| Ticagrelor | PF | VKORC1 | 79 | 1.0 | |
| Ticagrelor | PM | CYP2C9 | 29 | 0.3 | |
| Ticagrelor | PM | CYP2C19 | 17 | 0.2 | |
| Ticagrelor | UM | CYP2C19 | 31 | 0.4 | |
| Warfarin | PM | CYP2C19 | 1 | 0.0 | |
| CLD | Atorvastatin | PM | CYP3A5 | 827 | 43.2 |
| Atorvastatin | PF | ABCB1 | 200 | 10.4 | |
| Atorvastatin | PF | SLCO1B1 | 22 | 1.1 | |
| Fluvastatin | PM | CYP3A5 | 18 | 0.9 | |
| Fluvastatin | PF | ABCB1 | 7 | 0.4 | |
| Lovastatin | PM | CYP3A5 | 1 | 0.1 | |
| Pravastatin | PM | CYP3A5 | 35 | 1.8 | |
| Pravastatin | PF | ABCB1 | 8 | 0.4 | |
| Pravastatin | PF | SLCO1B1 | 2 | 0.1 | |
| Rosuvastatin | PM | CYP3A5 | 3 | 0.2 | |
| Simvastatin | PM | CYP3A5 | 742 | 38.8 | |
| Simvastatin | PF | ABCB1 | 194 | 10.1 | |
| Simvastatin | PF | SLCO1B1 | 16 | 0.8 | |
| Simvastatin | PM | CYP3A4 | 4 | 0.2 |
A/T anticoagulant/antiplatelet, CLD cholesterol-lowering drug, ASS acetylsalicylic acid, PF poor function, PM poor metabolizer, UM ultrarapid metabolizer.